End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
15.73 CNY | -1.07% | -4.78% | +47.56% |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- This company will be of major interest to investors in search of a high dividend stock.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+47.56% | 1.54B | - | ||
+43.31% | 6.19B | B- | ||
-16.99% | 4.48B | C+ | ||
+6.39% | 3.29B | C | ||
-13.10% | 3.12B | B- | ||
-4.17% | 2.5B | - | D+ | |
+45.47% | 1.94B | - | ||
-9.11% | 1.68B | - | - | |
-2.09% | 1.64B | - | - | |
-12.50% | 1.56B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300181 Stock
- Ratings Zhejiang Jolly Pharmaceutical Co.,LTD